Morgan Stanley’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-408,746
| Closed | -$15.7M | – | 7797 |
|
|
2023
Q2 | $15.7M | Buy |
408,746
+156,906
| +62% | +$4.03M | ﹤0.01% | 2721 |
|
|
2023
Q1 | $5.83M | Sell |
251,840
-30,171
| -11% | -$719K | ﹤0.01% | 3656 |
|
|
2022
Q4 | $7.39M | Sell |
282,011
-3,447
| -1% | -$76.4K | ﹤0.01% | 3378 |
|
|
2022
Q3 | $5.61M | Buy |
285,458
+54,724
| +24% | +$1.1M | ﹤0.01% | 3583 |
|
|
2022
Q2 | $4.04M | Buy |
230,734
+95,835
| +71% | +$1.5M | ﹤0.01% | 3953 |
|
|
2022
Q1 | $2.21M | Buy |
134,899
+59,543
| +79% | +$810K | ﹤0.01% | 4447 |
|
|
2021
Q4 | $1.23M | Buy |
75,356
+5,455
| +8% | +$77.7K | ﹤0.01% | 4927 |
|
|
2021
Q3 | $891K | Buy |
69,901
+2,756
| +4% | +$36.3K | ﹤0.01% | 5126 |
|
|
2021
Q2 | $948K | Buy |
67,145
+65,907
| +5,324% | +$1.05M | ﹤0.01% | 5110 |
|
|
2021
Q1 | $19K | Sell |
1,238
-20,860
| -94% | -$340K | ﹤0.01% | 6740 |
|
|
2020
Q4 | $351K | Buy |
22,098
+19,496
| +749% | +$294K | ﹤0.01% | 5278 |
|
|
2020
Q3 | $32K | Sell |
2,602
-3,115
| -54% | -$41.8K | ﹤0.01% | 5886 |
|
|
2020
Q2 | $66K | Buy |
5,717
+3,285
| +135% | +$45.3K | ﹤0.01% | 5578 |
|
|
2020
Q1 | $33K | Sell |
2,432
-16,379
| -87% | -$194K | ﹤0.01% | 5628 |
|
|
2019
Q4 | $111K | Buy |
18,811
+12,642
| +205% | +$68.7K | ﹤0.01% | 5624 |
|
|
2019
Q3 | $32K | Sell |
6,169
-7,177
| -54% | -$47.6K | ﹤0.01% | 5880 |
|
|
2019
Q2 | $103K | Buy |
13,346
+7,756
| +139% | +$118K | ﹤0.01% | 5308 |
|
|
2019
Q1 | $111K | Sell |
5,590
-51,333
| -90% | -$895K | ﹤0.01% | 5347 |
|
|
2018
Q4 | $751K | Buy |
56,923
+13,825
| +32% | +$276K | ﹤0.01% | 4499 |
|
|
2018
Q3 | $1.58M | Buy |
43,098
+967
| +2% | +$31K | ﹤0.01% | 4181 |
|
|
2018
Q2 | $1.47M | Buy |
42,131
+21,986
| +109% | +$843K | ﹤0.01% | 4337 |
|
|
2018
Q1 | $936K | Sell |
20,145
-14,426
| -42% | -$528K | ﹤0.01% | 4585 |
|
|
2017
Q4 | $1.3M | Sell |
34,571
-7,800
| -18% | -$341K | ﹤0.01% | 4367 |
|
|
2017
Q3 | $2.26M | Buy |
42,371
+9,311
| +28% | +$553K | ﹤0.01% | 3756 |
|
|
2017
Q2 | $1.88M | Buy |
33,060
+10,846
| +49% | +$544K | ﹤0.01% | 3856 |
|
|
2017
Q1 | $1.2M | Sell |
22,214
-3,171
| -12% | -$179K | ﹤0.01% | 4245 |
|
|
2016
Q4 | $1.45M | Buy |
25,385
+19,222
| +312% | +$1.16M | ﹤0.01% | 4185 |
|
|
2016
Q3 | $383K | Buy |
6,163
+4,443
| +258% | +$314K | ﹤0.01% | 4683 |
|
|
2016
Q2 | $97K | Sell |
1,720
-1,709
| -50% | -$104K | ﹤0.01% | 5254 |
|
|
2016
Q1 | $220K | Buy |
3,429
+410
| +14% | +$33.2K | ﹤0.01% | 4918 |
|
|
2015
Q4 | $424K | Buy |
3,019
+1,730
| +134% | +$235K | ﹤0.01% | 4653 |
|
|
2015
Q3 | $124K | Sell |
1,289
-1,627
| -56% | -$194K | ﹤0.01% | 5319 |
|
|
2015
Q2 | $442K | Buy |
+2,916
| New | +$482K | ﹤0.01% | 4804 |
|
Morgan Stanley's KDNY Position: Q3 2023 in Review
Morgan Stanley sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 408,746 shares — an estimated $15.7M sold.
Morgan Stanley first reported a position in KDNY in Q2 2015 and held it in 33 quarters. The position peaked at $15.7M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Morgan Stanley reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Morgan Stanley sold 408,746 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $15.7M.
- Morgan Stanley first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 33 quarters.
- Morgan Stanley's Chinook Therapeutics, Inc. Common Stock position peaked at $15.7M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.